Overview

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying the side effects of fosaprepitant dimeglumine and to see how well it works in treating patients with nausea and vomiting caused by chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
Aprepitant
Fosaprepitant